Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____ to ____ Commission File Number: 001-32295 FENNEC PHARMACEUTICALS INC. (Exact Name of Registrant as Specified in Its Charter) | --- | --- ...

FENNEC PHARMA ● June 2021 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the U.S. Food and Drug Administration (FDA), the status and timing of ongoing research, corporate partnering activities and other factors affe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 British Columbia, Canada (State or Other Jurisdiction of Incorporation or Organization 20-0442384 (I.R.S. Employer Identification No.) PO Box 13628, 68 TW Alexander Drive Research Triangle Park, North Carolina (Address of Principal Executive Offices) 27709 (Zip Code) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, no par value FENC Nasdaq Capital Market Emerging growth company ¨ FORM 10-Q ( ...

FENNEC PHARMA ● August 2020 | Corporate Presentation www.fennecpharma.com Safe Harbor Statement During the course of this presentation, we will make statements that constitute forward-looking statements. These statements may include operating expense projections, the initiation, timing and results of pending or future clinical trials, the actions or potential action of the U.S. Food and Drug Administration (FDA), the status and timing of ongoing research, corporate partnering activities and other factors af ...

| --- | --- | --- | |-------|-------|----------------------------------| | | | | | | | | | | | FENNEC PHARMA ● | | | (200 | September 2019 \| Corporate Deck | | --- | --- | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

| --- | --- | --- | |-------|-------|-------------------------------| | | | | | | | | | | | | | | | FENNEC PHARMA ● | | | | | | | ( 20 | August 2019 \| Corporate Deck | | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...